Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
CA 2367025 A1 · Owner: Genentech, Inc. · Inventors: Kramer, Susan M.; Dedrick, Russell L.; Starko, Karen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method is provided for reducing the occurrence of fever headache, nausea , and/or vomiting associated with administration of a therapeutic compound to a mammal in need therof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 17, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.